Distinguished in Thrombocytopenia

Dr. Sujatha Nallapareddy

Oncology
CommonSpirit Health
Rocky Mountain Cancer Centers LLP
701 E Hampden Ave, Ste 210, 
Littleton, CO 
Accepting New Patients
Offers Telehealth
Distinguished in Thrombocytopenia
CommonSpirit Health
Rocky Mountain Cancer Centers LLP
701 E Hampden Ave, Ste 210, 
Littleton, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sujatha Nallapareddy is an Oncologist in Littleton, Colorado. Dr. Nallapareddy is rated as a Distinguished provider by MediFind in the treatment of Thrombocytopenia. Her top areas of expertise are Pulmonary Embolism, Thrombocytopenia, Deep Vein Thrombosis, and Antiphospholipid Syndrome. Dr. Nallapareddy is currently accepting new patients.

Her clinical research consists of co-authoring 3 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Osmania Medical College
Residency
State University of New York at Buffalo
Specialties
Oncology
Licenses
Internal Medicine in CO
Board Certifications
Internal Medicine-American Board Of Internal Medicine (ABIM)
Hematology-American Board Of Internal Medicine (ABIM)
Medical Oncology-American Board Of Internal Medicine (ABIM)
Fellowships
University of Colorado School of Medicine (CU University of Colorado Anschutz Medical Campus)
Hospital Affiliations
The Medical Center Of Aurora & South Hospital
Littleton Adventist Hospital, Centura Health
Kit Carson County Memorial Hospital
Hca-Healthone Dba Swedish Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Rocky Mountain Cancer Centers LLP
701 E Hampden Ave, Ste 210, Littleton, CO 80120
Call: 303-805-7744

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug, Other
Study Drugs: Tucatinib, Trastuzumab, Ramucirumab, Paclitaxel
Study Phase: Phase 2/Phase 3
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

3 Total Publications

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Journal: The Lancet. Oncology
Published: July 19, 2012
View All 3 Publications
Similar Doctors
Distinguished in Thrombocytopenia
Dr. Nauman Moazzam
Oncology
Distinguished in Thrombocytopenia
Dr. Nauman Moazzam
Oncology

Rocky Mountain Cancer Centers LLP - Lakewood - Medical Oncol

11750 W 2nd Pl, Plz 1 Ste 160, 
Lakewood, CO 
 (18.9 miles away)
303-430-2700
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nauman Moazzam is an Oncologist in Lakewood, Colorado. Dr. Moazzam is rated as a Distinguished provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Chronic Familial Neutropenia, and Agranulocytosis. Dr. Moazzam is currently accepting new patients.

Distinguished in Thrombocytopenia
Dr. Douglas J. Kemme
Oncology | Palliative Medicine | Hematology
Distinguished in Thrombocytopenia
Dr. Douglas J. Kemme
Oncology | Palliative Medicine | Hematology

Poudre Valley Medical Group LLC

2500 Rocky Mountain Ave, 
Loveland, CO 
 (61.6 miles away)
970-203-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Douglas Kemme is an Oncologist and a Palliative Medicine provider in Loveland, Colorado. Dr. Kemme is rated as a Distinguished provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Neuroendocrine Tumor, Familial Pancreatic Cancer, Pancreatic Cancer, and RUNX1 Familial Platelet Disorder. Dr. Kemme is currently accepting new patients.

Distinguished in Thrombocytopenia
Dr. David J. Andorsky
Oncology
Distinguished in Thrombocytopenia
Dr. David J. Andorsky
Oncology

Rocky Mountain Cancer Centers LLP

4715 Arapahoe Ave, 
Boulder, CO 
 (38.7 miles away)
303-385-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Andorsky is an Oncologist in Boulder, Colorado. Dr. Andorsky is rated as a Distinguished provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), and Richter Syndrome. Dr. Andorsky is currently accepting new patients.

VIEW MORE THROMBOCYTOPENIA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nallapareddy's expertise for a condition
ConditionClose
    • Distinguished
    • Deep Vein Thrombosis
      Dr. Nallapareddy is
      Distinguished
      . Learn about Deep Vein Thrombosis.
      See more Deep Vein Thrombosis experts
    • Pulmonary Embolism
      Dr. Nallapareddy is
      Distinguished
      . Learn about Pulmonary Embolism.
      See more Pulmonary Embolism experts
    • Thrombocytopenia
      Dr. Nallapareddy is
      Distinguished
      . Learn about Thrombocytopenia.
      See more Thrombocytopenia experts
    • Advanced
    • Adult Immune Thrombocytopenia
      Dr. Nallapareddy is
      Advanced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • Agranulocytosis
      Dr. Nallapareddy is
      Advanced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Anemia
      Dr. Nallapareddy is
      Advanced
      . Learn about Anemia.
      See more Anemia experts
    • Antiphospholipid Syndrome
      Dr. Nallapareddy is
      Advanced
      . Learn about Antiphospholipid Syndrome.
      See more Antiphospholipid Syndrome experts
    • Arterial Embolism
      Dr. Nallapareddy is
      Advanced
      . Learn about Arterial Embolism.
      See more Arterial Embolism experts
    • Chronic B-Cell Leukemia (CBCL)
      Dr. Nallapareddy is
      Advanced
      . Learn about Chronic B-Cell Leukemia (CBCL).
      See more Chronic B-Cell Leukemia (CBCL) experts
    View All 29 Advanced Conditions
    • Experienced
    • Acquired Agranulocytosis
      Dr. Nallapareddy is
      Experienced
      . Learn about Acquired Agranulocytosis.
      See more Acquired Agranulocytosis experts
    • Acute Hepatic Porphyria (AHP)
      Dr. Nallapareddy is
      Experienced
      . Learn about Acute Hepatic Porphyria (AHP).
      See more Acute Hepatic Porphyria (AHP) experts
    • Acute Lymphoblastic Leukemia (ALL)
      Dr. Nallapareddy is
      Experienced
      . Learn about Acute Lymphoblastic Leukemia (ALL).
      See more Acute Lymphoblastic Leukemia (ALL) experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Nallapareddy is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Nallapareddy is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Nallapareddy is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    View All 66 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.